港股異動 | 康希諾生物-B大升12%,已開始重組新型冠狀病毒疫苗III期臨牀試驗
uSMART友信智投9月3日消息,週四港A兩市的疫苗股出現反彈行情,截至10:53分,康希諾生物-B市中最高升超12%,A股康希諾市中升超10%。
隔夜美股的疫苗板塊亦重獲資金流入。
9月2日午間,康希諾生物-B在披露易發佈公告稱,該公司已開始重組新型冠狀病毒疫苗(腺病毒5型載體)("Ad5- nCoV")的III期臨牀試驗。該公司已與NPO Petrovax Pharm,LLC簽訂協議。
根據該協議,公司和Petrovax將共同推進在俄羅斯進行Ad5-nCoV的三期臨牀試驗。該公司和Petrovax已收到俄羅斯聯邦衛生部關於Ad5-nCoV的臨牀試驗申請批準,並在俄羅斯開始Ad5-nCoV的III期臨牀試驗入組。此外,公司目前正在推動Ad5-nCoV的國際多中心III期臨牀試驗,並計劃在多個國家開展Ad5-nCoV的 III期臨牀試驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.